Millennium and glaxosmithkline announce integrilin~r (eptifibatide) injection licensing agreement for europe

摘要

Millennium Pharmaceuticals,Inc.and GlaxoSmithKline pic announced that they have entered into an agreement in which GSK will exclusively market INTEGRILIN in Europe.The commercialization alliance is designed to provide significant sales and marketing support to capitalize on growth opportunities for INTEGRILIN in Europe and will enhance the GSK cardiovascular critical care portfolio and presence in the European acute care market.